Evaluating the role of a liver-derived secretory protein, hepatokines, in atherosclerosis
Not Applicable
Recruiting
- Conditions
- atherosclerosis
- Registration Number
- JPRN-UMIN000025649
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Criteria for exclusion included cardiac mechanical support, biventricular pacemaker placement, hemodynamically significant uncorrected ventricular arrhythmia, serum creatinine level greater than 2.0 mg/dL, hemofiltration or dialysis, hypersensitivity for iodine, heparin or antiplatelet agent, malignant disease, comorbid conditions with an expected survival of less than 12 months, and active infection disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method concentration of hepatokines
- Secondary Outcome Measures
Name Time Method clinical characteristics, such as severity of atherosclerosis, profile of peripheral monocyte, cardiac or carotid artery echo and blood data.